Like type 1 diabetes, type 2 diabetes has long been considered a progressive, incurable condition in which the optimal goal after diagnosis is tight glycemic control and risk factor management to prevent vascular disease and neuropathy. The assumption that type 2 diabetes is irreversible is supported by the strong association with genetics, the high prevalence of microvascular complications, and the loss of beta cell mass and function frequently present at diagnosis.
The typical impact on morbidity and mortality for those with type 2 diabetes is rather grim and in excess of many cancers. The average 10-year survival rates for breast cancer and non-Hodgkin lymphoma are 84% and 55%, respectively; the average 10-year lifespan for type 2 diabetes is 50%. While the goal for most patients with cancer is remission, the patient with type 2 diabetes is taught that they need to live with this incurable disease. This need not be the case.
Increasing evidence points to the ability of patients to not only halt the onset of type 2 diabetes, but also to enter remission after a type 2 diabetes diagnosis. Bariatric surgery (RYGB, BPD) has been shown to result in durable remission in the majority of patients with type 2 diabetes, and research has demonstrated that counseling patients to engage in modest caloric reduction using portion control and limited use of meal replacements resulted in roughly 10% of patients experiencing remission after 2 years.
The Diabetes Remission Clinical Trial (DiRECT) in particular provides compelling evidence for the efficacy of structured, diet-induced weight loss on type 2 diabetes remission outcomes. The randomized controlled trial’s intervention consisted of withdrawal of antidiabetic/antihypertensive drugs, total diet replacement for 12 to 20 weeks, stepped food reintroduction (2 to 8 weeks), and then structured support for weight-loss maintenance. At 24 months, 36% of intervention group participants had remission of diabetes, lower weight (average 8 kg), lower blood pressure, a 50% reduction in cardiovascular disease risk, lower health care costs, and better quality of life. Post-hoc analysis of patients experiencing remission found a return to normal pancreas volume, morphology, and beta cell capacity. Importantly, the trial was conducted entirely in primary care practices, assisted by nurses and dietitians.
The evidence shows us that we can do better than simply managing type 2 diabetes. With sustained, diet-induced weight loss programs in patients who are willing to engage in substantial lifestyle modifications, remission of type 2 diabetes is possible. While such an outcome requires significant commitment from both patients and health care providers, the benefits of increasing type 2 diabetes remission rates to patients, the health care system, and society as a whole are impossible to ignore.
—Michael Lyon, MD, ABOM
This article is the opinion of the Nutrition Committee, a subcommittee of Doctors of BC’s Council on Health Promotion, and is not necessarily the opinion of Doctors of BC. This article has not been peer reviewed by the BCMJ Editorial Board.
3. Mingrone G, Panunzi S, Gaetano A, et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-973.
5. Jean M, Leslie W, Barnes C, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:344-355.
6. Al-Mrabeh A, Hollingsworth K, Shaw J, et al. 2-year remission of type 2 diabetes and pancreas morphology: A post-hoc analysis of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2020;8:939-948.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org